ProKidney Corp (PROK) Touts Reparencel Therapy for Growth [Yahoo! Finance]
ProKidney Corp. - Class A Ordinary Shares (PROK)
Company Research
Source: Yahoo! Finance
Global Healthcare Conference, the company reiterated its focus on the promising cell therapy, Reparencel. ProKidney Corp (PROK) Touts Reparencel Therapy for Growth yezry/Shutterstock.com The company anticipates top-line results from the cell therapy currently in Phase 3 of the Proactive One study by the second quarter of 2027. Enrollment in the ProAct One study is 50% complete, with the company targeting high-risk patients with chronic kidney disease and a GFR of 30 or less. ProKidney remains in a solid financial position, with $295 million in cash as of June, which is sufficient to bring the clinical trial to fruition. It has also started strengthening its manufacturing capacity in North Carolina in anticipation of strong demand. ProKidney Corp (NASDAQ:PROK) is a clinical-stage biotechnology company that develops a first-in-class cell therapy, rilparencel (also known as REACT), for the treatment of Chronic Kidney Disease (CKD). Its proprietary autologous cellular treatment uses a
Show less
Read more
Impact Snapshot
Event Time:
PROK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PROK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PROK alerts
High impacting ProKidney Corp. - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
PROK
News
- ProKidney GAAP EPS of -$0.12 beats by $0.02, revenue of $0.22M beats by $0.18M [Seeking Alpha]Seeking Alpha
- ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates [Yahoo! Finance]Yahoo! Finance
- ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical UpdatesGlobeNewswire
- ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025GlobeNewswire
- ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare ConferenceGlobeNewswire
PROK
Earnings
- 11/10/25 - In-Line
PROK
Sec Filings
- 11/19/25 - Form EFFECT
- 11/14/25 - Form 4
- 11/12/25 - Form 144
- PROK's page on the SEC website